ONKURE THERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
ONKURE THERAPEUTICS, INC. (OKUR) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $15.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-03-12
- ONKURE THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was -$113.10M, a 239.63% decline year-over-year.
- ONKURE THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-09-30 was $25.00M, a 68.35% decline year-over-year.
- ONKURE THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-06-30 was $45.00M, a 28.57% increase year-over-year.
- ONKURE THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-03-31 was $59.00M, a 25.53% increase year-over-year.
- ONKURE THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $15.90M, a 0.00% change from fiscal 2024.
- ONKURE THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $15.90M, a 93.43% decline from fiscal 2023.
- ONKURE THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $242.00M, a 448.75% increase from fiscal 2022.
- ONKURE THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $44.10M, a 435.97% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.90M 10-K · filed 2026-03-12 | |||
| 2024-12-31 | -$113.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$88.10M derived: sum of 2 quarters · filed 2025-03-10 | -$43.10M derived: sum of 3 quarters · filed 2025-03-10 | $15.90M 10-K · filed 2025-03-10 |
| 2024-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $70.00M derived: sum of 2 quarters · filed 2024-11-07 | $129.00M 10-Q · filed 2024-11-07 | $210.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $45.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $104.00M 10-Q · filed 2024-08-13 | $185.00M derived: sum of 3 quarters · filed 2024-08-13 | $264.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $59.00M 10-Q · filed 2024-05-07 | $140.00M derived: sum of 2 quarters · filed 2024-05-07 | $219.00M derived: sum of 3 quarters · filed 2024-11-07 | $254.00M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $81.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $160.00M derived: sum of 2 quarters · filed 2024-11-07 | $195.00M derived: sum of 3 quarters · filed 2024-11-07 | $242.00M 10-K · filed 2024-03-28 |
| 2023-09-30 | $79.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $114.00M derived: sum of 2 quarters · filed 2024-11-07 | $161.00M 10-Q · filed 2024-11-07 | $168.60M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $35.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $82.00M 10-Q · filed 2024-08-13 | $89.60M derived: sum of 3 quarters · filed 2024-08-13 | $95.60M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $47.00M 10-Q · filed 2024-05-07 | $54.60M derived: sum of 2 quarters · filed 2024-05-07 | $60.60M derived: sum of 3 quarters · filed 2024-05-07 | $69.60M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $13.60M derived: sum of 2 quarters · filed 2024-03-28 | $22.60M derived: sum of 3 quarters · filed 2024-03-28 | $44.10M 10-K · filed 2024-03-28 |
| 2022-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $15.00M derived: sum of 2 quarters · filed 2023-11-13 | $36.50M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $30.50M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $21.50M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $8.23M 10-K · filed 2023-03-27 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $1.20M derived: sum of 2 quarters · filed 2022-03-23 | $2.20M derived: sum of 3 quarters · filed 2022-03-23 | $7.40M 10-K · filed 2022-03-23 |
| 2020-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $2.20M derived: sum of 2 quarters · filed 2021-11-12 | $7.40M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $6.20M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | $5.20M 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |